OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Indexing: DOAJ-Directory of Open Access Journals.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2020, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 3.7 weeks (median values) after submission.
Haploidentical Stem Cell Transplantation
Submission Deadline: June 15, 2021 (Open) Submit Now
Mary A. Slatter, MD
Department of Immunology and BMT, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom;
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Research Interests: Transplantation; stem cell transplantation; bone marrow transplantation; hematopoietic stem cells; autoimmunity; cell transplantation
About This Topic
A major barrier to successful Hematopoietic stem cell transplantation has been the availability of HLA-identical donors, only available for 40-75% of eligible patients. An alternative is to use a mismatched or half-matched (haploidentical) related or unrelated donor and deplete the T-lymphocytes in the graft. Historically, the major challenges of using such T-depleted grafts were graft-versus-host disease (GVHD), graft failure, and high transplant-related mortality. A number of new methods of T-depletion are now revolutionising the field. These include use of a replete mismatched graft followed by post-transplant cyclophosphamide which selectively depletes donor alloreactive T-lymphocytes, or in vitro T-depletion using a magnetic column to attract an organic iron bead bound to an antibody to selectively remove T-lymphocytes bearing the αβ T-lymphocyte receptor, associated with GVHD, and retain the γδ T-lymphocyte receptor-bearing cells which confer antiviral and graft-versus-leukemia affects, as well as Natural Killer cells, and lymphocyte precursors. This method also provides a platform for additional cellular therapy such as memory T-lymphocyte add-back, viral specific cytotoxic T-lymphocytes, or mismatched T-lymphocytes with an added caspase suicide gene which can be switched off if GVHD occurs.
In this special issue on Haploidentical Stem Cell Transplantation, submissions related to this topic are invited. Original research or review articles, in adult or pediatric populations are welcome for submission.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.